The Dutch biopharma Crucell said the SFDA released its hepatitis B vaccine Hepavax-Gene® for registration and quality control in China. Crucell pointed out that Hepavax-Gene offers two advantages over competing products: its production is based on Crucell's hansenula polymorpha patented technology, a protein expression platform, and the vaccine is completely free of the mercury-based compound thiomersal. In many countries, thiomersal is being phased out from vaccines given to children because of potentially adverse effects. More details...
Stock Symbol: (NSDQ: CRXL)